The results showed that the addition of Irinotecan, guided by the UGT1A1 genotype, to Capecitabine-based neoadjuvant chemoradiotherapy led to a significant increase in complete tumor response among Chinese patients (47). The gene discussed is UGT1A1; the disease is neoplasm.